Ranbaxy receives approval to mkt Loperamide Hydrochloride

39820 Investors following Ranbaxy Labs. Share this News with them.

0

Like this story, share it with millions of investors on M3

Ranbaxy receives approval to mkt Loperamide Hydrochloride

Ranbaxy receives USFDA approval to market loperamide hydrochloride and simethicone tablets

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Ranbaxy wins on 2 additional Atorvastatin patents in Norway Ranbaxy wins 2 Lipitor patent cases in Norway Ranbaxy launches Soliten for treatment of urology disorder ALSO READ See latest News about Ranbaxy Labs See previous management interviews See what other Experts & Brokerages are saying about Ranbaxy Labs Ranbaxy Labs BSE | NSE 28/05/12 Are Mutual Funds betting on Ranbaxy Labs?

Ohm Laboratories Inc., based in North Brunswick, New Jersey, USA, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company.  Ohm is engaged in the sale and distribution of generic and branded private label, OTC products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development.  The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 8 countries.

Sourced From: Ranbaxy Laboratories Ltd